Status:
COMPLETED
A Long-Term Safety Study to Evaluate Methylphenidate HCL Tablets at Multiple Dose Levels in Adults With Attention Deficit Hyperactivity Disorder
Lead Sponsor:
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Conditions:
Attention Deficit Hyperactivity Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the long-term safety of methylphenidate HCL extended-release tablets at five dose levels in adults with Attention Deficit Hyperactivity Disorder (ADHD)
Detailed Description
This is a multicenter, open-label, dose-titration, long-term study to evaluate the long-term safety of five dose levels of methylphenidate HCL extended-release tablets, 36 mg, 54 mg, 72 mg (two 36 mg ...
Eligibility Criteria
Inclusion
- Investigator determined diagnosis of ADHD as defined by the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria with symptomatology from childhood to adulthood, symptoms present before age seven years and continue to meet full DSM-IV criteria at time of assessment
- Diagnosis confirmed by the Adult ADHD Clinical Diagnostic Scale (ACDS) at Baseline and Adult ADHD Investigator Symptom Rating Scale (AISRS) score of 24 or greater as determined by the Investigator at Baseline
- Global Assessment of Functioning (GAF) Scale score of 41 to 60, inclusive, at Baseline
- Minimum weight of 100 lbs (45.4 kg) at Screening
- Negative urine drug test at the Screening and Baseline Visits when tested for drugs of abuse
Exclusion
- Known to be non-responders to methylphenidate or other stimulants for the treatment of ADHD
- History of allergy, sensitivity or contraindication to methylphenidate or components of methylphenidate HCl extended-release tablets
- Coexisting medical condition or taking concomitant medication that would interfere with safe administration of methylphenidate in the Investigator's opinion
- Known structural cardiac abnormality
- Diagnosis of or family history of Tourette's syndrome, or motor or verbal tics
- History of seizures or a seizure disorder other than febrile seizures in childhood
- Glaucoma
- Uncontrolled hyperthyroidism or hypothyroidism
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
560 Patients enrolled
Trial Details
Trial ID
NCT00326300
Start Date
April 1 2006
End Date
August 1 2007
Last Update
May 24 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.